Drug Trial Radar · NCT01555151
Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma
Last checked: Nov 19, 2026Latest source record: May 1, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
739
Actual
Start
Jul 2012
Primary completion
Jul 2013
Study completion Jul 2013
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 15, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy, safety and pharmacokinetics of Mometasone furoate delivered via Concept1 device or Twisthaler® device in adult and adolescent patients with persistent asthma.
Conditions
- Asthma
Interventions
Mometasone furoateDrug
Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device
Concept 1Device
A single dose dry powder inhaler (SDDPI)
TwisthalerDevice
A single dose dry powder inhaler (SDDPI)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Trough Forced Expiratory Volume in 1 Second (FEV1)Time frame: Day 29
Locations
165 sites in 17 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Kortrijk, Belgium, Belgium
Novartis Investigative Site
Liège, Belgium, Belgium
Novartis Investigative Site
Niagara Falls, Ontario, Canada
Novartis Investigative Site
Windsor, Ontario, Canada
Novartis Investigative Site
Mirabel, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Québec, Quebec, Canada
Novartis Investigative Site
Trois-Rivières, Quebec, Canada
Novartis Investigative Site
Kohtla-Järve, Estonia, Estonia
Novartis Investigative Site
Tallinn, Estonia, Estonia
Novartis Investigative Site
Tartu, Estonia, Estonia
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Goch, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Berlin, Germany, Germany
Novartis Investigative Site
Berlin, Germany, Germany
Novartis Investigative Site
Berlin, Germany, Germany
Novartis Investigative Site
Berlin, Germany, Germany
Novartis Investigative Site
Berlin, Germany, Germany
Novartis Investigative Site
Berlin, Germany, Germany
Novartis Investigative Site
Essen, Germany, Germany
Novartis Investigative Site
Hamburg, Germany, Germany
Novartis Investigative Site
Leipzig, Germany, Germany
Novartis Investigative Site
Lübeck, Germany, Germany
Novartis Investigative Site
Reinfeld, Germany, Germany
Novartis Investigative Site
Schwerin, Germany, Germany
Novartis Investigative Site
Baja, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Gödöllő, Hungary
Novartis Investigative Site
Győr, Hungary
Novartis Investigative Site
Gyula, Hungary
Novartis Investigative Site
Kistelek, Hungary
Novartis Investigative Site
Makó, Hungary
Novartis Investigative Site
Mohács, Hungary
Novartis Investigative Site
Mosonmagyaróvár, Hungary
Novartis Investigative Site
Nagykanizsa, Hungary
Novartis Investigative Site
Szombathely, Hungary
Showing 40 of 165 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.